Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

GLUE

Monte Rosa Therapeutics Inc

Feb 13 • 04:00PM ET

17.92

-0.58 -3.14 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BPMC FATE SRPT PTCT EXEL ADPT SGMO EDIT

| Held by: AVUV VTI XBI IWM VXF IWN IBB SCHA BSVO VTWO

Index	RUT	P/E	58.68	EPS (ttm)	0.31	Insider Own	37.42%	Shs Outstand	61.79M	Perf Week	-8.34%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-1.38	Insider Trans	-0.09%	Shs Float	47.71M	Perf Month	-25.52%
Enterprise Value	1.02B	PEG	-	EPS next Q	-0.33	Inst Own	62.18%	Short Float	16.06%	Perf Quarter	26.55%
Income	20.95M	P/S	7.53	EPS this Y	78.43%	Inst Trans	-4.86%	Short Ratio	4.85	Perf Half Y	311.95%
Sales	181.54M	P/B	4.50	EPS next Y	-553.52%	ROA	5.41%	Short Interest	7.66M	Perf YTD	14.29%
Book/sh	3.98	P/C	3.49	EPS next 5Y	-16.50%	ROE	9.28%	52W High	25.77 -30.46%	Perf Year	166.67%
Cash/sh	5.13	P/FCF	9.42	EPS past 3/5Y	14.78% -41.09%	ROIC	7.43%	52W Low	3.50 411.99%	Perf 3Y	171.93%
Dividend Est.	-	EV/EBITDA	60.28	Sales past 3/5Y	- -	Gross Margin	95.41%	Volatility	6.18% 6.43%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.59	EPS Y/Y TTM	116.97%	Oper. Margin	4.69%	ATR (14)	1.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.54	Sales Y/Y TTM	1112.27%	Profit Margin	11.54%	RSI (14)	37.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.54	EPS Q/Q	-12.99%	SMA20	-14.88%	Beta	1.64	Target Price	33.80
Payout	-	Debt/Eq	0.16	Sales Q/Q	38.54%	SMA50	-7.68%	Rel Volume	0.47	Prev Close	18.50
Employees	134	LT Debt/Eq	0.15	Earnings	Nov 06 BMO	SMA200	77.08%	Avg Volume	1.58M	Price	17.92
IPO	Jun 24, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.91% 73.85%	Trades		Volume	743,165	Change	-3.14%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $11
Feb-15-24	Initiated	Wedbush	Outperform	$11
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$18
Oct-13-22	Initiated	UBS	Buy	$22
Aug-15-22	Initiated	Jefferies	Buy	$20
Apr-28-22	Initiated	Credit Suisse	Neutral	$19
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$19
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20

Feb-05-26 11:37AM	3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher (MarketBeat)
Jan-16-26 08:39PM	Staar Surgical, Alumis, and More Stocks See Action From Activist Investors (Barrons.com)
Jan-08-26 10:49PM	Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +8.72%
11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
08:55AM	Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
04:01PM	Loading…
Jan-07-26 04:01PM	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +45.41%
12:00PM	Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why (Zacks)
11:21AM	Stocks Hover Near Record Highs on Mixed US Economic News (Barchart)
10:07AM	Stocks Supported by Lower Bond Yields (Barchart)
07:00AM	Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects (GlobeNewswire)
Jan-06-26 04:05PM	Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results (GlobeNewswire) +11.18%
Dec-17-25 07:11AM	Monte Rosa Therapeutics announces data from Phase 1/2 study of MRT-2359 (TipRanks) -10.24%
Dec-16-25 04:22PM	Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High (Investor's Business Daily) +13.43%
07:00AM	Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations (GlobeNewswire)
Dec-15-25 04:01PM	Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results (GlobeNewswire)
11:30AM	Loading…
Nov-08-25 11:30AM	Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases (GlobeNewswire)
Nov-06-25 08:30AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.69%
07:34AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-03-25 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.07%
Oct-24-25 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases (GlobeNewswire) +7.32%
Sep-30-25 11:42AM	Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects (Insider Monkey)
Sep-16-25 09:49AM	Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis (Zacks) -6.64%
08:01AM	Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-15-25 12:31PM	Novartis returns to Monte Rosa for second time in a year with $5.7bn deal (Pharmaceutical Technology) +44.07%
08:24AM	Monte Rosa surges premarket on Novartis collaboration deal (Investing.com)
07:15AM	Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics (Reuters)
07:00AM	Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases (GlobeNewswire)
05:39AM	Novartis dives deeper into protein degraders with second Monte Rosa deal (BioPharma Dive)
07:00AM	Loading…
Sep-02-25 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 08:25AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:22AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-06-25 06:00PM	Certara, Inc. (CERT) Q2 Earnings Miss Estimates (Zacks) -9.83%
Jul-22-25 07:30AM	Monte Rosa doses first subjects in trial of MRT-8102 for inflammatory conditions (Clinical Trials Arena)
Jul-21-25 07:00AM	Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases (GlobeNewswire)
Jul-03-25 02:15PM	Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines (GlobeNewswire)
Jun-11-25 08:38AM	Monte Rosa Therapeutics receives FDA clearance for MRT-8102 IND (Pharmaceutical Business Review)
Jun-10-25 07:00AM	Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases (GlobeNewswire)
Jun-09-25 09:55AM	Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet (Zacks)
May-28-25 07:00AM	Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-25 08:25AM	Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates (Zacks) +9.61%
07:21AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-06-25 08:20AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.69%
May-01-25 08:15AM	Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-28-25 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire)
Mar-24-25 04:46PM	Monte Rosa Therapeutics: Exercise Extreme Caution (SeekingAlpha)
Mar-21-25 12:04PM	Monte Rosa Therapeutics Inc (GLUE) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com) -17.85%
09:33AM	Mixed data results for two Monte Rosa molecular glue degraders (Clinical Trials Arena)
Mar-20-25 12:42PM	Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 (SeekingAlpha) +5.37%
12:00PM	Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
10:35AM	Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates (Zacks)
07:00AM	Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs (GlobeNewswire)
Mar-11-25 07:00AM	Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -6.11%
Jan-11-25 07:27AM	Monte Rosa Therapeutics provide corporate update, key milestones 2025 (TipRanks)
Jan-10-25 07:00AM	Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 (GlobeNewswire)
Jan-06-25 07:00AM	Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-13-24 07:00AM	Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors (GlobeNewswire)
Dec-11-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire) -9.85%
07:00AM	Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders (GlobeNewswire)
Dec-06-24 07:11AM	Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study (TipRanks) +6.57%
Dec-05-24 07:00AM	Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors (GlobeNewswire)
Dec-02-24 05:44PM	Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? (Zacks)
Nov-26-24 07:00AM	Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-15-24 09:55AM	Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet (Zacks) -8.73%
Nov-13-24 07:00AM	Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -5.48%
Nov-07-24 08:35AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice (Zacks)
Oct-30-24 09:55AM	Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade (Zacks)
Oct-29-24 11:50AM	Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler (TipRanks)
10:57AM	Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis (GuruFocus.com)
Oct-28-24 05:40PM	Monte Rosa Almost Doubles Up 94% On A Massive Deal With Novartis (Investor's Business Daily) +93.87%
02:26PM	This Biotech Stock Has Doubled Its Value Today Here's Why (Investopedia)
02:10PM	Monte Rosa Stock Doubles Up 127% On A Massive Deal With Novartis (Investor's Business Daily)
08:53AM	Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs (Reuters)
08:46AM	Why Is Monte Rosa Therapeutics Stock Surging On Monday? (Benzinga)
07:33AM	Monte Rosa joins with Novartis in molecular glue drug deal (BioPharma Dive)
07:00AM	Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders (GlobeNewswire)
Oct-23-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors (GlobeNewswire) -8.29%
Aug-28-24 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.50%
Aug-19-24 07:00AM	Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study (GlobeNewswire)
Aug-08-24 08:15AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.25%
07:15AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-08-24 08:36AM	Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day (GlobeNewswire) +6.87%
Jun-27-24 07:00AM	Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 (GlobeNewswire) -8.40%
Jun-14-24 08:45AM	Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis (GlobeNewswire)
May-30-24 07:00AM	Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
07:00AM	Monte Rosa Therapeutics Announces Leadership Team Promotions (GlobeNewswire)
May-21-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease (GlobeNewswire) -13.23%
May-16-24 01:09PM	Monte Rosa Therapeutics Prices $100 Million Public Offering (MT Newswires)
07:00AM	Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering (GlobeNewswire)
May-15-24 04:01PM	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-10-24 03:26PM	Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview (GuruFocus.com) -6.37%
May-09-24 01:55PM	GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Warmuth Markus	President & CEO	Jan 07 '26	Sale	23.49	5,466	128,373	618,937	Jan 09 04:05 PM
Warmuth Markus	Officer	Jan 07 '26	Proposed Sale	23.49	5,466	128,372		Jan 07 04:58 PM
Nickson Philip	Chief Business & Legal Officer	Jan 05 '26	Sale	15.17	3,155	47,861	60,845	Jan 05 04:06 PM
Champoux Jennifer	Chief Operating Officer	Jan 05 '26	Sale	15.17	2,629	39,882	62,371	Jan 05 04:05 PM
Dunn Edmund	Principal Accounting Officer	Jan 05 '26	Sale	15.17	1,039	15,762	22,693	Jan 05 04:04 PM
Warmuth Markus	President & CEO	Jan 05 '26	Sale	15.17	10,135	153,748	624,403	Jan 05 04:04 PM
Janku Filip	Chief Medical Officer	Jan 05 '26	Sale	15.17	3,155	47,861	75,026	Jan 05 04:04 PM
Warmuth Markus	Officer	Jan 05 '26	Proposed Sale	15.17	10,135	153,759		Jan 05 04:01 PM
Dunn Edmund	Principal Accounting Officer	Jun 03 '25	Sale	4.45	2,062	9,174	23,732	Jun 04 04:15 PM
Leo Chandra P.	Director	Mar 24 '25	Buy	5.84	10,000	58,383	10,000	Mar 25 06:32 PM

Open in Screener

BDTX

Black Diamond Therapeutics Inc

Feb 13 • 04:00PM ET

2.22

+0.03 1.37 %

Healthcare • Biotechnology • USA • NASD

BDTX Black Diamond Therapeutics Inc daily Stock Chart

Peers: BPMC FATE IGMS ALLO ADAP TVRD XFOR CRBP

| Held by: VTI VXF FESM IBB BSVO DFAS PRFZ IWC DFSV EES

Index	-	P/E	6.12	EPS (ttm)	0.36	Insider Own	21.46%	Shs Outstand	56.94M	Perf Week	-1.55%
Market Cap	126.48M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	0.00%	Shs Float	44.75M	Perf Month	-20.43%
Enterprise Value	10.65M	PEG	-	EPS next Q	-0.18	Inst Own	65.10%	Short Float	9.24%	Perf Quarter	-54.41%
Income	21.50M	P/S	1.81	EPS this Y	135.14%	Inst Trans	-0.63%	Short Ratio	3.52	Perf Half Y	-20.43%
Sales	70.00M	P/B	1.00	EPS next Y	-241.20%	ROA	14.54%	Short Interest	4.13M	Perf YTD	-8.64%
Book/sh	2.22	P/C	0.93	EPS next 5Y	11.38%	ROE	19.23%	52W High	4.94 -55.06%	Perf Year	-5.13%
Cash/sh	2.38	P/FCF	5.92	EPS past 3/5Y	28.55% -5.22%	ROIC	15.12%	52W Low	1.20 85.77%	Perf 3Y	-23.97%
Dividend Est.	-	EV/EBITDA	0.87	Sales past 3/5Y	- -	Gross Margin	99.51%	Volatility	4.94% 5.99%	Perf 5Y	-91.72%
Dividend TTM	-	EV/Sales	0.15	EPS Y/Y TTM	127.88%	Oper. Margin	16.94%	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.94	Sales Y/Y TTM	-	Profit Margin	30.71%	RSI (14)	37.20	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	8.94	EPS Q/Q	45.77%	SMA20	-8.73%	Beta	3.37	Target Price	9.29
Payout	-	Debt/Eq	0.16	Sales Q/Q	-	SMA50	-13.26%	Rel Volume	0.41	Prev Close	2.19
Employees	24	LT Debt/Eq	0.13	Earnings	Nov 06 BMO	SMA200	-23.36%	Avg Volume	1.17M	Price	2.22
IPO	Jan 30, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	35.98% -	Trades		Volume	476,650	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Downgrade	Guggenheim	Buy → Neutral
Nov-18-25	Resumed	Piper Sandler	Overweight	$9
Oct-16-25	Resumed	Stifel	Buy	$8
Sep-04-25	Initiated	Guggenheim	Buy	$8
Jul-01-25	Resumed	Raymond James	Outperform	$11
Jul-31-24	Initiated	Raymond James	Outperform	$20
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy	$2 → $10
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$11
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform	$10
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold	$10
Jan-07-21	Initiated	Wedbush	Outperform	$45
Nov-24-20	Initiated	Berenberg	Buy	$58
May-04-20	Initiated	H.C. Wainwright	Buy	$53
Feb-24-20	Initiated	JP Morgan	Overweight	$42
Feb-24-20	Initiated	Jefferies	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	Canaccord Genuity	Buy	$50

Show Previous Ratings

Feb-02-26 09:56AM	Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker (Insider Monkey)
Jan-23-26 09:40AM	Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-09-26 12:00PM	What Makes Black Diamond (BDTX) a New Strong Buy Stock (Zacks)
06:23AM	New Strong Buy Stocks for January 9th (Zacks)
Dec-31-25 11:12AM	Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data (Insider Monkey)
09:35AM	Loading…
Dec-04-25 09:35AM	Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) (Zacks)
Dec-03-25 07:01AM	Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM (GlobeNewswire) -22.03%
Dec-02-25 04:01PM	Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update (GlobeNewswire) -8.49%
Nov-28-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-12-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks) +5.41%
09:15AM	Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Nov-06-25 04:01PM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:37AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-25 02:00PM	Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings? (Zacks)
09:24AM	Loading…
Oct-22-25 09:24AM	BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now? (Zacks) -5.05%
Oct-15-25 09:20AM	Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX? (Zacks) +10.37%
Oct-09-25 09:52AM	BDTX Stock Hits 52 Week High: Is There More Room for Growth? (Zacks) +8.27%
09:40AM	Is Medpace (MEDP) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-07-25 09:15AM	Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-25-25 12:53PM	Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment? (Zacks)
Sep-23-25 10:23AM	BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? (Zacks) -7.31%
Sep-22-25 09:40AM	Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-16-25 09:47AM	Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results (Insider Monkey)
Sep-12-25 09:08AM	Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? (Zacks)
Sep-05-25 10:53AM	BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth? (Zacks)
Sep-04-25 10:46AM	Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX? (Zacks)
Aug-19-25 12:00PM	Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why (Zacks)
Aug-18-25 09:40AM	Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year? (Zacks)
Aug-07-25 07:47AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance) -15.24%
07:30AM	Loading…
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-15-25 04:58PM	Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise (Insider Monkey)
May-29-25 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) +13.07%
May-12-25 04:05PM	Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.71% +10.29%
Apr-26-25 11:00AM	Microsoft, Apple Set To Report Earnings As Markets Watch Out For Core PCE Price Index (Seeking Alpha)
Mar-31-25 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-25 12:58AM	Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier (SeekingAlpha)
Mar-20-25 10:42AM	Servier and Black Diamond sign deal for solid tumours therapy (Pharmaceutical Technology) +9.30%
Mar-19-25 07:00AM	Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy (GlobeNewswire)
Mar-06-25 04:09PM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 09:15AM	NAYA Biosciences Announces Nomination of New Board Members (GlobeNewswire)
Jan-12-25 06:05AM	Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-05-24 09:00AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance) +8.70%
08:00AM	Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.47%
Oct-07-24 04:01PM	Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway (GlobeNewswire)
Sep-23-24 11:43AM	Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug (Benzinga) -5.46%
07:00AM	Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations (GlobeNewswire)
Sep-22-24 10:00AM	Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC (GlobeNewswire)
Sep-14-24 03:30AM	Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-08-24 04:05PM	Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors (GlobeNewswire) +6.25%
12:00PM	All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy (Zacks)
Aug-06-24 01:53PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024 (InvestorPlace) -5.57%
07:37AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-29-24 08:28PM	Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-01-24 10:00AM	Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-29-24 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 08:23AM	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating (MT Newswires)
May-10-24 08:46AM	Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings? (Zacks) -9.48%
May-09-24 01:54PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:28AM	Black Diamond: Q1 Earnings Snapshot (Associated Press Finance)
Apr-29-24 08:50AM	Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Apr-25-24 09:55AM	Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect? (Zacks)
Apr-24-24 04:05PM	Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-15-24 12:00PM	Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-11-24 08:00AM	Black Diamond Therapeutics Announces Changes to Board of Directors (GlobeNewswire) +11.85%
Apr-08-24 09:55AM	Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know (Zacks) +5.73%
Apr-07-24 06:00PM	Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting (GlobeNewswire)
Apr-03-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.71%
Mar-22-24 09:55AM	How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93% (Zacks) +6.10%
Mar-14-24 05:31AM	Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ... (GuruFocus.com) +8.35%
Mar-12-24 08:32AM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance) -5.50%
08:00AM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024 (GlobeNewswire)
Feb-28-24 08:00AM	Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-04-24 08:00AM	Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones (GlobeNewswire)
Dec-13-23 07:00AM	Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM (GlobeNewswire) -9.03%
Nov-07-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-23 08:07AM	Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update (GuruFocus.com)
07:48AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance)
07:45AM	Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-20-23 12:54PM	Hedge Fund and Insider Trading News: John Paulson, Sanjay Shah, Doug Kass, Point72 Asset Management, Balyasny Asset Management, Black Diamond Therapeutics, Inc. (BDTX), Delta Air Lines, Inc. (DAL), and More (Insider Monkey)
Oct-14-23 12:30PM	Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535 (GlobeNewswire)
Oct-04-23 12:14PM	Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -5.56%
Sep-18-23 12:34PM	Co-founder of cancer biotech Black Diamond replaced as CEO (American City Business Journals)
07:00AM	Black Diamond Therapeutics Announces CEO Transition (GlobeNewswire)
Sep-11-23 08:00AM	Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-05-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-11-23 07:35AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-25-23 07:43AM	Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jul-16-23 10:05AM	TipRanks Perfect 10 List: These Monster Growth Stocks Could Reach New Highs (TipRanks)
Jun-29-23 08:57PM	Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -12.22%
05:48PM	Why Shares of Black Diamond Therapeutics Skyrocketed This Week (Motley Fool)

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH GROWTH N V	10% Owner	Mar 19 '25	Sale	2.07	5,784,292	11,997,749	2,733,547	Mar 20 09:01 PM

Open in Screener

TPST

Tempest Therapeutics Inc

Feb 13 • 04:00PM ET

2.36

+0.05 2.16 %

Healthcare • Biotechnology • USA • NASD

TPST Tempest Therapeutics Inc daily Stock Chart

Peers: IMMP ADAP ATNM AGEN AFMD HOOK KALA COGT ONCY MRKR

| Held by: VTI VXF DCOR DFAC

Index	-	P/E	-	EPS (ttm)	-10.10	Insider Own	6.28%	Shs Outstand	4.93M	Perf Week	-1.67%
Market Cap	31.82M	Forward P/E	-	EPS next Y	-2.76	Insider Trans	0.00%	Shs Float	4.62M	Perf Month	-7.45%
Enterprise Value	32.71M	PEG	-	EPS next Q	-0.62	Inst Own	15.88%	Short Float	3.13%	Perf Quarter	-72.87%
Income	-36.05M	P/S	-	EPS this Y	68.72%	Inst Trans	-2.03%	Short Ratio	0.93	Perf Half Y	-75.11%
Sales	0.00M	P/B	1.65	EPS next Y	54.75%	ROA	-141.49%	Short Interest	0.14M	Perf YTD	-17.77%
Book/sh	1.43	P/C	4.24	EPS next 5Y	51.10%	ROE	-405.03%	52W High	12.37 -80.92%	Perf Year	-80.53%
Cash/sh	0.56	P/FCF	-	EPS past 3/5Y	41.44% 50.16%	ROIC	-265.02%	52W Low	2.16 9.26%	Perf 3Y	-90.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.95% 9.01%	Perf 5Y	-99.53%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	49.43%	Oper. Margin	-	ATR (14)	0.22	Perf 10Y	-99.98%
Dividend Ex-Date	-	Quick Ratio	2.30	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.27	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.30	EPS Q/Q	85.13%	SMA20	-8.76%	Beta	-2.37	Target Price	11.00
Payout	-	Debt/Eq	1.32	Sales Q/Q	-	SMA50	-16.29%	Rel Volume	0.20	Prev Close	2.31
Employees	25	LT Debt/Eq	1.14	Earnings	Nov 05 BMO	SMA200	-65.73%	Avg Volume	155.26K	Price	2.36
IPO	Nov 12, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	30,865	Change	2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-26	Upgrade	H.C. Wainwright	Neutral → Buy	$11
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$13
Feb-08-24	Initiated	Jefferies	Buy	$15

Feb-11-26 06:59AM	Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets (GlobeNewswire)
Feb-04-26 04:47PM	Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets (GlobeNewswire) -6.30%
Jan-20-26 05:20PM	Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders (GlobeNewswire) -5.15%
Nov-26-25 04:05PM	Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Nov-25-25 08:00AM	Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.26%
09:00AM	Loading…
Nov-19-25 09:00AM	Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 (GlobeNewswire) -48.59%
Nov-05-25 08:30AM	Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +9.10%
Aug-13-25 08:00AM	Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer (Business Wire) +6.02%
Aug-11-25 04:12PM	Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.83% +9.99%
Jun-30-25 08:00AM	Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China (GlobeNewswire)
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-11-25 08:00AM	Tempest Announces $4.6 Million Registered Direct Offering of Common Stock (GlobeNewswire) -15.88%
Jun-06-25 11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 08:00AM	Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC (GlobeNewswire) +15.16%
May-13-25 04:28PM	Tempest Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
04:05PM	Loading…
Apr-28-25 04:05PM	Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting (GlobeNewswire) -6.26%
Apr-21-25 08:00AM	Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP (GlobeNewswire)
Apr-10-25 11:05AM	TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up (Zacks) -18.04%
Apr-09-25 04:30PM	Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value (GlobeNewswire) +9.87%
Mar-27-25 04:10PM	Tempest Reports Year End 2024 Financial Results and Provides Business Update (GlobeNewswire) -8.08%
Mar-25-25 04:30PM	Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-13-25 08:00AM	FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Feb-10-25 08:00AM	Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (GlobeNewswire)
Feb-07-25 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-25 08:00AM	Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) (GlobeNewswire)
Dec-06-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 09:00PM	A Reverse Aging Gurus Trail of Failed Businesses (The Wall Street Journal)
Nov-25-24 04:30PM	Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 04:21PM	Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.50%
08:00AM	Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma (GlobeNewswire)
07:01AM	Loading…
Oct-10-24 07:01AM	Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial (GlobeNewswire) -18.52%
07:00AM	Tempest Extends Limited Duration Stockholder Rights Plan (GlobeNewswire)
Sep-20-24 04:30PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-18-24 08:00AM	Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs (GlobeNewswire) -6.62%
Sep-05-24 08:00AM	Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +5.04%
Aug-23-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 08:00AM	Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance (GlobeNewswire)
Aug-15-24 08:00AM	Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma (GlobeNewswire) +30.25%
Aug-08-24 04:56PM	Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -14.18%
Jun-20-24 08:13AM	Why Is Tempest Therapeutics (TPST) Stock Up 45% Today? (InvestorPlace) -29.47%
08:00AM	Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm (GlobeNewswire)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 06:22PM	Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Jun-07-24 04:30AM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-21-24 08:00AM	Tempest to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 04:29PM	Tempest Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.34%
Apr-26-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 08:00AM	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications (GlobeNewswire) -12.20%
Mar-19-24 09:53PM	TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:25PM	Tempest Reports Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types (GlobeNewswire)
Mar-05-24 04:30PM	Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting (GlobeNewswire) +16.09%
Feb-26-24 08:00AM	Tempest to Present at the 44th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-02-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.60%
Dec-01-23 04:15PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-23 08:00AM	Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +9.25%
Nov-08-23 05:17PM	Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.74% +16.31%
Oct-12-23 08:25AM	Why Is Tempest Therapeutics (TPST) Stock Down 35% Today? (InvestorPlace) -59.26%
Oct-11-23 04:29PM	TPST Stock: 7 Things to Know About Tempest Therapeutics (InvestorPlace) +3,972.53%
08:01AM	Tempest Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
08:00AM	Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study (GlobeNewswire)
07:41AM	Why Is Tempest Therapeutics (TPST) Stock Up 325% Today? (InvestorPlace)
Oct-10-23 04:05PM	Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Sep-19-23 08:00AM	Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Sep-05-23 08:00AM	Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 04:13PM	Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Jul-19-23 08:00AM	Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together (GlobeNewswire)
May-31-23 04:05PM	Tempest to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.85% -5.88%
May-25-23 05:00PM	Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers (GlobeNewswire) -9.76%
May-19-23 04:05PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 04:15PM	Tempest Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 08:00AM	Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire) +23.26%
Apr-27-23 04:58PM	Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Apr-26-23 06:41PM	Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting (GlobeNewswire) -6.74%
Apr-17-23 09:00AM	Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting (GlobeNewswire) +25.42%
Mar-22-23 05:26PM	Tempest Reports Year End 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.52%
Mar-15-23 04:05PM	Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting (GlobeNewswire)
Mar-14-23 04:30PM	Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting (GlobeNewswire) +15.79%
Nov-22-22 04:05PM	Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-10-22 09:00AM	Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer (GlobeNewswire)
Nov-08-22 08:00AM	Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -12.09%
Nov-02-22 08:00AM	Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting (GlobeNewswire) +8.72%
Oct-06-22 08:00AM	Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit (GlobeNewswire)
Sep-07-22 08:00AM	Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +11.40%
Aug-15-22 08:00AM	Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +15.81%
Jul-07-22 08:00AM	Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference (GlobeNewswire) +11.93%
Jun-09-22 08:00AM	Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance (GlobeNewswire)
Jun-06-22 04:05PM	Tempest to Present at the Jefferies Healthcare Conference (GlobeNewswire) -12.50%
May-26-22 04:57PM	Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting (GlobeNewswire) -26.68%
May-13-22 08:00AM	Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights (GlobeNewswire) +5.88%
Apr-27-22 10:01AM	Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting (GlobeNewswire) +30.08%
08:00AM	Tempest Announces Private Placement Financing of $15 Million (GlobeNewswire)
Apr-08-22 01:00PM	Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting (GlobeNewswire)
Mar-29-22 04:00PM	Tempest Reports Year End 2021 Financial Results and Provides Business Update (GlobeNewswire) -7.89%
Mar-10-22 08:00AM	Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire) -9.23%
Mar-08-22 04:30PM	Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-09-22 08:00AM	Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference (GlobeNewswire)
Nov-18-21 08:00AM	Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab (GlobeNewswire)

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

GLUE

Monte Rosa Therapeutics Inc

BDTX

Black Diamond Therapeutics Inc

TPST

Tempest Therapeutics Inc

Upgrade your FINVIZ experience